Study group | Asthma severity | Subjects | Bronchoscopies | Symptoms# | Symptoms# per bronchoscopy | Mild % | Moderate % | Severe % | Hospital admissions¶ (subjects) | Hospital admissions¶ per bronchoscopy |
Feasibility study | Mild to moderate | 16 | 49 | 155 | 3.2 | 84 | 16 | 0 | 0 | 0 |
AIR | Moderate to severe | 55 | 161 | 407 | 2.5 | 69 | 28 | 3 | 6 (4) | 0.04 |
AIR2: thermoplasty group | Moderate to severe | 190 | 558 | 573 | 1.0 | 44 | 53 | 3.1 | 19 (16) | 0.034 |
AIR2: sham group | Moderate to severe | 98 | 292 | 206 | 0.7 | 55 | 40 | 1.5 | 2 (2) | 0.007 |
RISA | Severe | 15 | 45 | 136 | 3.0 | 49 | 41 | 10 | 7 (4) | 0.156 |
Data are presented as n, unless otherwise stated. AIR: Asthma Intervention Research; RISA: Research in Severe Asthma. #: respiratory-related adverse events during the treatment period (from first bronchoscopy to 6 weeks after the final bronchoscopy); ¶: during the treatment period.